{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:14:25Z","timestamp":1793834065393,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00125-020-05265-7","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T09:44:28Z","timestamp":1598867068000},"page":"2434-2445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":231,"title":["Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)"],"prefix":"10.1007","volume":"63","author":[{"given":"Mohammad S.","family":"Kuchay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Krishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra S.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasjeet S.","family":"Wasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parjeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep K.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarannum","family":"Bano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid J.","family":"Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrish","family":"Mithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"issue":"16","key":"5265_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/nejmra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346(16):1221\u20131231. https:\/\/doi.org\/10.1056\/nejmra011775","journal-title":"N Engl J Med"},{"issue":"9","key":"5265_CR2","doi-asserted-by":"publisher","first-page":"e25269","DOI":"10.1371\/journal.pone.0025269","volume":"6","author":"S Sharma","year":"2011","unstructured":"Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA (2011) GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 6(9):e25269. https:\/\/doi.org\/10.1371\/journal.pone.0025269","journal-title":"PLoS One"},{"issue":"1","key":"5265_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.21006","volume":"43","author":"X Ding","year":"2006","unstructured":"Ding X, Saxena NK, Lin S, Gupta NA, Anania FA (2006) Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology 43(1):173\u2013181. https:\/\/doi.org\/10.1002\/hep.21006","journal-title":"Hepatology"},{"issue":"2","key":"5265_CR4","doi-asserted-by":"publisher","first-page":"e31394","DOI":"10.1371\/journal.pone.0031394","volume":"7","author":"J Lee","year":"2012","unstructured":"Lee J, Hong SW, Chae SW et al (2012) Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice. PLoS One 7(2):e31394. https:\/\/doi.org\/10.1371\/journal.pone.0031394","journal-title":"PLoS One"},{"issue":"8","key":"5265_CR5","doi-asserted-by":"publisher","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","volume":"302","author":"JL Trevaskis","year":"2012","unstructured":"Trevaskis JL, Griffin PS, Wittmer C et al (2012) Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302(8):G762\u2013G772. https:\/\/doi.org\/10.1152\/ajpgi.00476.2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"5265_CR6","doi-asserted-by":"publisher","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","volume":"302","author":"JE Mells","year":"2012","unstructured":"Mells JE, Fu PP, Sharma S et al (2012) GLP-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 302(2):G225\u2013G235. https:\/\/doi.org\/10.1152\/ajpgi.00274.2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"5265_CR7","doi-asserted-by":"publisher","first-page":"172594","DOI":"10.1016\/j.ejphar.2019.172594","volume":"861","author":"JY Zhou","year":"2019","unstructured":"Zhou JY, Poudel A, Welchko R et al (2019) Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. Eur J Pharmacol 861:172594. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172594","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"5265_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1507\/endocrj.ej16-0449","volume":"64","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, Nakano Y, Fukuda T et al (2017) Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J 64(3):269\u2013281. https:\/\/doi.org\/10.1507\/endocrj.ej16-0449","journal-title":"Endocr J"},{"issue":"2","key":"5265_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbrc.2018.09.134","volume":"505","author":"W Zhu","year":"2018","unstructured":"Zhu W, Feng PP, He K, Li SW, Gong JP (2018) Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet. Biochem Biophys Res Commun 505(2):523\u2013529. https:\/\/doi.org\/10.1016\/j.bbrc.2018.09.134","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"5265_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbrc.2016.05.086","volume":"476","author":"Q He","year":"2016","unstructured":"He Q, Sha S, Sun L, Zhang J, Dong M (2016) GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK\/mTOR pathway. Biochem Biophys Res Commun 476(4):196\u2013203. https:\/\/doi.org\/10.1016\/j.bbrc.2016.05.086","journal-title":"Biochem Biophys Res Commun"},{"key":"5265_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jnutbio.2018.07.009","volume":"62","author":"GV Moreira","year":"2018","unstructured":"Moreira GV, Azevedo FF, Ribeiro LM et al (2018) Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem 62:143\u2013154. https:\/\/doi.org\/10.1016\/j.jnutbio.2018.07.009","journal-title":"J Nutr Biochem"},{"issue":"3","key":"5265_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3892\/ijmm.2014.1826","volume":"34","author":"T Kawaguchi","year":"2014","unstructured":"Kawaguchi T, Itou M, Taniguchi E, Sata M (2014) Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and \u0394-5-desaturase index in a murine model of non-alcoholic steatohepatitis. Int J Mol Med 34(3):782\u2013787. https:\/\/doi.org\/10.3892\/ijmm.2014.1826","journal-title":"Int J Mol Med"},{"issue":"2","key":"5265_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1210\/jc.2016-2775","volume":"102","author":"JM Petit","year":"2017","unstructured":"Petit JM, Cercueil JP, Loffroy R et al (2017) Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab 102(2):407\u2013415. https:\/\/doi.org\/10.1210\/jc.2016-2775","journal-title":"J Clin Endocrinol Metab"},{"issue":"10019","key":"5265_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s0140-6736(15)00803-x","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/s0140-6736(15)00803-x","journal-title":"Lancet"},{"issue":"12","key":"5265_CR15","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","volume":"59","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MHA et al (2016) Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia 59(12):2588\u20132593. https:\/\/doi.org\/10.1007\/s00125-016-4100-7","journal-title":"Diabetologia"},{"issue":"7","key":"5265_CR16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2337\/dc14-2548","volume":"38","author":"A Tang","year":"2015","unstructured":"Tang A, Rabasa-Lhoret R, Castel H et al (2015) Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care 38(7):1339\u20131346. https:\/\/doi.org\/10.2337\/dc14-2548","journal-title":"Diabetes Care"},{"key":"5265_CR17","first-page":"131","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L (2015) Trulicity (dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits 8:131\u2013134","journal-title":"Am Health Drug Benefits"},{"issue":"10193","key":"5265_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/s0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"10","key":"5265_CR19","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/dme.13697","volume":"35","author":"K Cusi","year":"2018","unstructured":"Cusi K, Sattar N, Garc\u00eda-P\u00e9rez LE et al (2018) Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet Med 35(10):1434\u20131439. https:\/\/doi.org\/10.1111\/dme.13697","journal-title":"Diabet Med"},{"issue":"5","key":"5265_CR20","doi-asserted-by":"publisher","first-page":"e0154206","DOI":"10.1371\/journal.pone.0154206","volume":"11","author":"Z Li","year":"2016","unstructured":"Li Z, Zhang Y, Quan X et al (2016) Efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists among type 2 diabetes: a systematic review and network meta-analysis. PLoS One 11(5):e0154206. https:\/\/doi.org\/10.1371\/journal.pone.0154206","journal-title":"PLoS One"},{"issue":"6","key":"5265_CR21","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/hep.26455","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin M, Lam J, Peterson MR et al (2013) Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58(6):1930\u20131940. https:\/\/doi.org\/10.1002\/hep.26455","journal-title":"Hepatology"},{"issue":"6","key":"5265_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/apt.12237","volume":"37","author":"NS Patel","year":"2013","unstructured":"Patel NS, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R (2013) Association between novel MRI-estimated pancreatic fat and liver histology determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 37(6):630\u2013639. https:\/\/doi.org\/10.1111\/apt.12237","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"5265_CR23","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.26543","volume":"58","author":"SB Reeder","year":"2013","unstructured":"Reeder SB (2013) Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. Hepatology 58(6):1877\u20131880. https:\/\/doi.org\/10.1002\/hep.26543","journal-title":"Hepatology"},{"issue":"15","key":"5265_CR24","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3748\/wjg.15.1869","volume":"15","author":"JS Lee","year":"2009","unstructured":"Lee JS, Kim SH, Jun DW et al (2009) Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol 15(15):1869\u20131875. https:\/\/doi.org\/10.3748\/wjg.15.1869","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5265_CR25","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1038\/ctg.2014.5","volume":"5","author":"M Hori","year":"2014","unstructured":"Hori M, Takahashi M, Hiraoka N et al (2014) Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol 5(3):e53. https:\/\/doi.org\/10.1038\/ctg.2014.5","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"5265_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2337\/dc16-0836","volume":"40","author":"MM Smits","year":"2017","unstructured":"Smits MM, Tonneijck L, Muskiet MHA et al (2017) Pancreatic effects of liraglutide or sitagliptin in overweight patients with type 2 diabetes: a 12-week randomized, placebo-controlled trial. Diabetes Care 40(3):301\u2013308. https:\/\/doi.org\/10.2337\/dc16-0836","journal-title":"Diabetes Care"},{"issue":"8","key":"5265_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care 41(8):1801\u20131808. https:\/\/doi.org\/10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"5265_CR28","doi-asserted-by":"publisher","first-page":"E253","DOI":"10.1111\/j.1530-0277.2012.01898.x","volume":"37","author":"JA Johnson","year":"2013","unstructured":"Johnson JA, Lee A, Vinson D, Seale JP (2013) Use of AUDIT-based measures to identify unhealthy alcohol use and alcohol dependence in primary care: a validation study. Alcohol Clin Exp Res 37(Suppl 1):E253\u2013E259. https:\/\/doi.org\/10.1111\/j.1530-0277.2012.01898.x","journal-title":"Alcohol Clin Exp Res"},{"key":"5265_CR29","doi-asserted-by":"publisher","unstructured":"American Diabetes Association (2018) Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S55\u2013S64. https:\/\/doi.org\/10.2337\/dc18-s006","DOI":"10.2337\/dc18-s006"},{"key":"5265_CR30","doi-asserted-by":"publisher","unstructured":"American Diabetes Association (2018) Lifestyle management: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S38\u2013S50. https:\/\/doi.org\/10.2337\/dc18-s004","DOI":"10.2337\/dc18-s004"},{"issue":"4","key":"5265_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/ajg.2014.1","volume":"109","author":"VW Wong","year":"2014","unstructured":"Wong VW, Wong GL, Yeung DK et al (2014) Fatty pancreas, insulin resistance, and \u03b2-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol 109(4):589\u2013597. https:\/\/doi.org\/10.1038\/ajg.2014.1","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"5265_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/hep.27647","volume":"61","author":"R Loomba","year":"2015","unstructured":"Loomba R, Sirlin CB, Ang B et al (2015) Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61(4):1239\u20131250. https:\/\/doi.org\/10.1002\/hep.27647","journal-title":"Hepatology"},{"issue":"2","key":"5265_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","volume":"65","author":"J Cui","year":"2016","unstructured":"Cui J, Philo L, Nguyen P et al (2016) Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 65(2):369\u2013376. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.021","journal-title":"J Hepatol"},{"issue":"2","key":"5265_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2):367\u2013378. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"issue":"4","key":"5265_CR35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/01.sla.0000179652.07502.3f","volume":"242","author":"SG Mattar","year":"2005","unstructured":"Mattar SG, Velcu LM, Rabinovitz M et al (2005) Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242(4):610\u2013617. https:\/\/doi.org\/10.1097\/01.sla.0000179652.07502.3f","journal-title":"Ann Surg"},{"issue":"5","key":"5265_CR36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547\u20131554. https:\/\/doi.org\/10.1002\/hep.27368","journal-title":"Hepatology"},{"key":"5265_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1475-2840-12-77","volume":"12","author":"WC Wu","year":"2013","unstructured":"Wu WC, Wang CY (2013) Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol 12:77. https:\/\/doi.org\/10.1186\/1475-2840-12-77","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"5265_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1158\/1055-9965.epi-04-0583","volume":"14","author":"AV Patel","year":"2005","unstructured":"Patel AV, Rodriguez C, Bernstein L et al (2005) Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. Cancer Epidemiol Biomark Prev 14(2):459\u2013466. https:\/\/doi.org\/10.1158\/1055-9965.epi-04-0583","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"16","key":"5265_CR39","doi-asserted-by":"publisher","first-page":"9116","DOI":"10.1073\/pnas.161284298","volume":"98","author":"H Yamashita","year":"2001","unstructured":"Yamashita H, Takenoshita M, Sakurai M et al (2001) A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A 98(16):9116\u20139121. https:\/\/doi.org\/10.1073\/pnas.161284298","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 2","key":"5265_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2010.01275.x","volume":"12","author":"P Ferre","year":"2010","unstructured":"Ferre P, Foufelle F (2010) Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12(Suppl. 2):83\u201392. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01275.x","journal-title":"Diabetes Obes Metab"},{"key":"5265_CR41","doi-asserted-by":"publisher","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML et al (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305(16):1659\u20131668. https:\/\/doi.org\/10.1001\/jama.2011.520","DOI":"10.1001\/jama.2011.520"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-020-05265-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T20:04:37Z","timestamp":1630353877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-020-05265-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5265"],"URL":"https:\/\/doi.org\/10.1007\/s00125-020-05265-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}